Overview

SEvoflurane for Sedation in ARds

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates whether a sedation with inhaled sevoflurane will decrease mortality and increase time off the ventilator at 28 days in patients with acute respiratory distress syndrome (ARDS). Half of the patients will receive inhaled sedation with sevoflurane and the other half will receive intravenous sedation with propofol.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Clermont-Ferrand
Treatments:
Propofol
Sevoflurane